GlassScriptPhysician profile
Tracy Yager
NPI 1689068611
$7,792.98
in general payments reported to CMS, 2019-2025
32 companies · $1,513 in 2025
The $1,513 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,141 · 2022: $1,849 · 2023: $2,097 · 2024: $1,193 · 2025: $1,513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,650 · Education: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,649.69 |
| Education | $152.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,183.28 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $893.92 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $853.43 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $779.20 | 2021-2025 | Cuvitru, Takhzyro, Eohilia |
| Amgen INC. | $568.35 | 2021-2025 | Tezspire |
| Genzyme Corporation | $446.23 | 2021-2025 | |
| Csl Behring | $412.64 | 2021-2025 | Hizentra, Andembry, Haegarda |
| Kaleo, INC. | $294.25 | 2021-2024 | Auvi-Q |
| Optinose US, INC. | $272.15 | 2021-2025 | |
| Incyte Corporation | $255.25 | 2021-2023 | Opzelura |
| Pfizer INC. | $246.25 | 2021-2025 | |
| Ucb, INC. | $166.24 | 2023 | |
| Biocryst US Sales Co., LLC | $159.90 | 2022-2025 | Orladeyo |
| Leo Pharma INC. | $133.30 | 2022-2023 | Adbry |
| Ars Pharmaceuticals Operations, INC. | $120.35 | 2025 | Neffy |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $116.55 | 2021-2024 | Xembify, Prolastin-C Liquid, Gamunex-C |
| Sanofi-Aventis U.S. LLC | $98.99 | 2025 | |
| Novartis Pharmaceuticals Corporation | $98.00 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.30 | 2021-2022 | |
| Octapharma USA, INC. | $79.64 | 2023-2024 | Cutaquig |
| Teva Pharmaceuticals USA, INC. | $73.17 | 2022-2023 | Airduo Digihaler |
| Pharming Healthcare, INC. | $64.80 | 2022-2025 | Ruconest |
| Genentech USA, INC. | $59.08 | 2021-2022 | |
| Ionis Pharmaceuticals, INC. | $57.22 | 2025 | Dawnzera |
| Blueprint Medicines Corporation | $55.69 | 2023-2024 | Ayvakit |
| Lilly USA, LLC | $50.32 | 2025 | Ebglyss |
| Hikma Pharmaceuticals USA | $42.20 | 2023 | Ryaltris |
| Eyevance Pharmaceuticals LLC | $37.56 | 2021 | |
| Abbvie INC. | $25.45 | 2023 | |
| Aimmune Therapeutics, INC. | $22.96 | 2022 | |
| Paratek Pharmaceuticals, INC. | $22.18 | 2025 | Xhance |
| Alk-Abello, INC | $22.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Yager listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.